Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 48

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 48
---
     |     4.2 |     | 03/04/2025  |
| 4.12    |     | Form of Series B Warrant                                                                                                                                                          |     | 8-K                       |     | 001-34375   |     |     4.3 |     | 03/04/2025  |
| 5.1*    |     | Opinion of Sullivan & Worcester LLP.                                                                                                                                              |     |                           |     |             |     |         |     |             |
| 10.1+   |     | Patent and Know-How License Agreement, dated March 29, 2020, by and between Plus Therapeutics, Inc. and NanoTx, Corp.                                                             |     | 8-K                       |     | 001-34375   |     |    10.1 |     | 03/30/2020  |

II-6

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83

|         |     |                                                                                                                                                                          |     | Incorporated by Reference |     |             |     |         |     |             |
| Exhibit 
 Number  |     | Description                                                                                                                                                              |     | Form                      |     | File Number |     | Exhibit |     | Filing Date |
| 10.2+   |     | Patent & Technology License Agreement, dated December 31, 2021, by and between Plus Therapeutics, Inc. and the University of Texas Health Science Center at San Antonio. |     | 10-K                      |     | 001-34375   |     |    10.2 |     | 02/24/2022  |
| 10.3    |     | Equity Distribution Agreement, dated September 9, 2022, by and between Plus Therapeutics, Inc. and Canaccord Genuity LLC.                                                |     | 8-K                       |     | 001-34375   |     |     1.1 |     | 09/09/2022  |
| 10.4    |     | Purchase Agreement, dated August 2, 2022, by and between Lincoln Park Capital Fund, LLC and Plus Therapeutics, Inc.                                                      |     | 8-K                       |     | 001-34375   |     |    10.1 |     | 08/08/2022  |
| 10.